Clinical trial
Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric…
NCT00392288 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00392288 |
|---|---|
| Title | Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma. |
| Official title | A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 μg BID or 40 μg BID for 12 Weeks in Patients Aged 4 to <12 Years With Persistent Asthma. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Ciclesonide, Placebo |
| Enrollment | 528 |
| Start date | Sep 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Oct 25, 2006 |
| Last update posted | Feb 1, 2017 |
| Countries | Hungary, Mexico, Poland, Russia, South Africa, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: